Single rapamycin administration induces prolonged downward shift in defended body weight in rats.
Manipulation of body weight set point may be an effective weight loss and maintenance strategy as the homeostatic mechanism governing energy balance remains intact even in obese conditions and counters the effort to lose weight. However, how the set point is determined is not well understood. We show that a single injection of rapamycin (RAP), an mTOR inhibitor, is sufficient to shift the set point in rats. Intraperitoneal RAP decreased food intake and daily weight gain for several days, but surprisingly, there was also a long-term reduction in body weight which lasted at least 10 weeks without additional RAP injection. These effects were not due to malaise or glucose intolerance. Two RAP administrations with a two-week interval had additive effects on body weight without desensitization and significantly reduced the white adipose tissue weight. When challenged with food deprivation, vehicle and RAP-treated rats responded with rebound hyperphagia, suggesting that RAP was not inhibiting compensatory responses to weight loss. Instead, RAP animals defended a lower body weight achieved after RAP treatment. Decreased food intake and body weight were also seen with intracerebroventricular injection of RAP, indicating that the RAP effect is at least partially mediated by the brain. In summary, we found a novel effect of RAP that maintains lower body weight by shifting the set point long-term. Thus, RAP and related compounds may be unique tools to investigate the mechanisms by which the defended level of body weight is determined; such compounds may also be used to complement weight loss strategy.
Department of Psychology, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
Mark
M
Hebert
Division of Biomedical Sciences, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
Maria
M
Licursi
Department of Psychology, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
Brittany
B
Jensen
Department of Psychology, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
Ashley
A
Baker
Department of Psychology, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
Steve
S
Milway
Department of Psychology, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
Charles
C
Malsbury
Department of Psychology, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
Virginia L
VL
Grant
Department of Psychology, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
Robert
R
Adamec
Division of Biomedical Sciences, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
Michiru
M
Hirasawa
Department of Psychology, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
Jacqueline
J
Blundell
D000273:Adipose Tissue / Q000187:drug effects; D000818:Animals; D001835:Body Weight / Q000187:drug effects*; D001921:Brain / Q000378:metabolism; D004357:Drug Synergism; D004435:Eating / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects; D006706:Homeostasis / Q000187:drug effects; D007267:Injections; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology*; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D013997:Time Factors
D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus